Skip to content
The Nexus
DossierENTITY

IL-13

Coverage of IL-13 in the Nexus archive.

Earliest in view: Jun 22 · 11:45 UTCMost recent: Jun 22 · 11:45 UTC
Co-mentioned in this coverage
AbbVieorganization1Apogee Therapeuticsorganization1zumilokibarttopic1Financial Timesorganization1
Recent coverage
  • BUSINESSJun 22 · 11:45 UTCSTAT NEWS
    STAT+: AbbVie to buy Apogee Therapeutics in nearly $11B deal

    AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion in cash, valuing the company at $135.11 per share, a 50% premium over its previous closing price. The deal focuses on Apogee's lead drug, zumilokibart, which targets IL-13 and is being tested for inflammatory diseases like atopic dermatitis and asthma.